Rice Biotech Launch Pad welcomes Carolyn Ng to external advisory board

Written by Emily J. Thompson, Senior Investment Analyst

BOLD-2.48%

BCYC-0.91%

BCAX+1.93%

Source: Newsfilter

Updated: Jul 31 2025

0mins

Source: Newsfilter

Appointment of Carolyn Ng: Carolyn Ng has been appointed to the external advisory board of the Rice Biotech Launch Pad, bringing her extensive experience in biotech and company building to support the accelerator's mission of translating health and medical technology discoveries into effective therapies.
Role of the Rice Biotech Launch Pad: The Rice Biotech Launch Pad aims to expedite the transition of innovative research from Rice University into clinical studies and commercialization, contributing to Houston's growth as a leading biotech hub.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy BOLD?" and start using high-conviction signals backed by rigorous historical data.

BOLD

$1.18+Infinity%1D

Analyst Views on BOLD

Wall Street analysts forecast BOLD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BOLD is 4.00 USD with a low forecast of 4.00 USD and a high forecast of 4.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Analyst Rating

1 Buy

0 Hold

0 Sell

Moderate Buy

Current: 1.210

Low

4.00

Averages

4.00

High

4.00

Current: 1.210

Low

4.00

Averages

4.00

High

4.00

H.C. Wainwright

Buy

downgrade

$5 -> $4

2025-08-11

Reason

H.C. Wainwright

Price Target

$5 -> $4

AI Analysis

2025-08-11

downgrade

Buy

Reason

H.C. Wainwright lowered the firm's price target on Boundless Bio to $4 from $5 and keeps a Buy rating on the shares following the Q2 report.

Goldman Sachs

Richard Law

initiated

2025-07-24

Reason

Goldman Sachs

Richard Law

Price Target

2025-07-24

initiated

Reason

Goldman Sachs analyst Richard Law initiated coverage of Boundless Bio with an Early-Stage Biotech rating, saying the company's combo approach for its lead asset BBI-355 comes with high risk.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for BOLD

Unlock Now

About BOLD

Boundless Bio, Inc. is a clinical-stage oncology company, which is engaged in cancer therapeutics that address the unmet need in patients with oncogene amplified tumors by targeting extrachromosomal DNA (ecDNA). Using its proprietary Spyglass platform, it identifies targets essential for ecDNA functionality in oncogene amplified cancer cells, then designs and develops small molecule drugs called ecDNA-directed therapeutic candidates (ecDTx) to inhibit those targets. The Company’s lead therapeutic candidate ecDTx, BBI-355, is an oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells. BBI-355 demonstrated CHK1 inhibition and tumor regressions in oncogene amplified preclinical cancer models, including those enabled by ecDNA, and is being studied in a first-in-human, Phase I/II clinical trial in patients with oncogene amplified cancers. Its next program is directed at a previously undrugged kinesin target.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

GET FREE REAL TIME NOTIFICATIONS

Stock Monitor for BOLD?

Get Started Free

FREE STOCK RECOMMENDATIONS DAILY

Stock Bullish Tomorrow

Get Started Free

70% BACKTESTED ACCURACY!

Should I Buy BOLD?

Get Started Free

Top News

Boundless Bio Reports Second Quarter 2025 Financial Results and Business Highlights

Aug 05 2025Newsfilter

POTENTIATE Trial Enrollment: Boundless Bio has opened enrollment for the BBI-355 and BBI-825 combination arm of the POTENTIATE trial, expecting to deliver initial proof-of-concept clinical data within its cash runway timeline.
Financial Overview: The company reported a net loss of $15.7 million for Q2 2025, with $127 million in cash supporting operations through expected clinical readouts into 2028.